Skip to main content
Premium Trial:

Request an Annual Quote

BGI to Launch Desktop Sequencer in October; Instrument Will Run NIFTY Noninvasive Prenatal Test

NEW YORK (GenomeWeb) – BGI said late last week that it plans to launch a desktop sequencer called BGISEQ-500 in October.

BGISEQ-500 will be based on Complete Genomics' technology and will automate sample preparation, sequencing, and data analysis.

BGI also plans to run its noninvasive prenatal test, NIFTY, on the new instrument. Turnaround time for the test, from library construction to data analysis, will be 24 hours, and each run will multiplex between 16 and 192 samples.

A year ago, the China Food and Drug Administration approved the NIFTY test on two sequencing platforms — BGISEQ-100 and BGISEQ-1000 — which are based on Thermo Fisher Scientific's Ion Torrent platform and Complete Genomics' technology, respectively.

BGI said it will make more details about the BGISEQ-500 instrument available during the 10th International Conference on Genomics in Shenzhen in October.

The company announced in January that it plans to commercialize two next-gen sequencing systems — a large-scale platform and a desktop instrument — this year but provided no further details at the time.

Earlier this month, it provided first details on Revolocity, a high-throughput sequencing system that will initially be able to sequence 10,000 human genomes per year and has a list price of $12 million.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.